Exclusive: Global early stage accelerator program launches second Texas location in Houston

New to town

Palo Alto-based Founder Institute is launching its Houston program at Station Houston. Image courtesy Founder Institute

Silicon Valley-based Founder Institute has announced its second Texas program in Houston, which will operate out of Station Houston. Founder Institute Houston applications for the inaugural cohort close May 19.

The early stage accelerator focuses on advancing startup companies in the pre-funding phase.

"It's quite different from any other program in Houston currently," says Neal Murthy, director of Founder Institute Houston. "It's an accelerator, but it's an idea-stage accelerator."

Before Founder Institute, Houston's only early stage opportunities were tied to universities — like the University of Houston's Red Labs or Rice University's Owl Spark — and those are typically focused on the university's community and on education, Murthy says.

In anticipation of launch, Founder Institute Houston will host a series of free entrepreneurial events, with the first one being March 19.

The Houston chapter will be ran by three directors: Murthy, a UH lecturer and angel investor, James Phelan, innovation expert with a real estate background, and Tabbie Saenz, Alice community leader and Baker Ripley mentor. Martin Martinez, managing director of Founder Institute Texas, who launched the Austin program, will also join the team.

"What's nice about our team is because we were already colleagues and friends prior to coming together on this project, we already have rapor, we can communicate, and we know each other's working styles, strengths, and weaknesses," says Phelan.

Founded in 2009 by Adeo Ressi and Jonathan Greechan, Founder Institute has chapters in 180 cities in 65 countries. They've contributed to 3,500 companies that have now raised over $800 million.

"Houston's supportive startup community and its affordable living costs have inspired a lot of entrepreneurial enthusiasm in the city. Every year, more co-working spaces and incubators move to Houston and it's now easier to launch a startup here than ever before. We aim to help that trend," Ressi says in a release. "I believe that our structured accelerator program will give potential founders the guidance they need to launch successful technology companies in Houston."

Every chapter focuses on the same idea-stage type of company and selects around 30 companies to participate in a 14-week course of education, mentorship, and business development. The cohort spends around three hours a week in educational programming, but then is expected to spend 20 to 25 hours a week working assignments and business development. It's designed to be tough. Usually, only around 10 founders of the 30 will cross the finish line.

"If they can't handle this course, then there's no way they're going to be a successful founder because this course is a breeze compared to running a company," says Phalen.

The Founder Institute alumni network is huge, and is one of the program's biggest perks. Not only do participants get access to a network successful founders, but they also usually have a foot in the door at the next stage of competitive accelerator programs.

"That's an enormously valuable thing from a fundraising aspect if you have the support from another successful founder standing next to you, vouching for you," Phelan says.

Another thing that makes Founder Institute different is, rather than operating off an equity approach, Founder Institute and its local directors receive warrants from each participating company. And, fellow founders and even program mentors receive a cut too.

"The sharing of that [means] everyone has economic incentives and it encourages collaboration among the cohort itself," Murthy says.

Founder Institute's expansion plan for Texas doesn't end at Austin and Houston. Two other locations in Dallas and San Antonio are also in route to the Lone Star State. However, Houston's a bit different of a city to be in, with it's diversity and large size.

"We are going to be targeting a very diverse community as well. We want to have everyone who hasn't had a chance to access resources like this," Saenz says.

Murthy, who has been a mentor for the Founder Institute in Austin, says it's so remarkable to see how much these founders accomplish in the 14 weeks, and he can't wait to see that affect the Houston ecosystem.

"We think that Houston needs a number of new elements to fill out its ecosystem, and this is one of them — an idea-stage accelerator," Murthy says. "We've seen the success it's had in Austin and globally, and we're hoping to bring that to Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings